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Introduction
The CCAAT/Enhancer Binding Protein (CEBP) genes belong to a subfamily of transcription factors sharing a basic region -leucine zipper (bZIP) motif within their carboxy terminal end.
They can homo-and heterodimerize through the bZIP motif. Alternative splicing and multiple translational initiation sites add further complexity to the family picture 1 .
CEBPA, the founder member of the family, is encoded from a gene composed of a single exon, localized to the chromosomal band 19q13. Expression studies and knock-out experiments have demonstrated its essential role in the control of balance between proliferation and differentiation in a range of tissues, including hematopoietic stem cells and different stages of myeloid differentiation [2] [3] [4] . CEBPA controls the expression of myeloid genes and interacts with many protein partners such as CDK2, CDK4, CDKN1A/p21, E2F and the SPI1/PU.1 transcription factor. The interaction with E2F is essential for the repression of MYC expression and induction of granulocytic differentiation. Besides the full-length 42kDa protein, an internal translational initiation site leads to the synthesis of a smaller 30kDa product. This product fails to inhibit E2F and to down-regulate MYC and acts as a dominant negative form 5, 6 .
In line with its essential role in myeloid differentiation, inactivation of CEBPA is observed in human myeloid leukemic samples Both constitutive and somatic mutations are frequently associated with mutation or loss of the second copy of the CEBPA gene, related to progression of the oncogenic process 7, 8 . A comparable mechanism is observed in chronic myelogenous leukemia, in which the expression of hnRNPE2 is responsible for the translational inhibition of CEBPA in blast crisis.
More recently, functional inactivation of the CEBPA protein has been described in association with FLT3 internal tandem duplication 9 . Together, these data support a tumor suppressor role for the CEBPA gene in myeloid malignancies.
Chromosomal translocations are frequently observed in hematological malignancies, representing an important step in the leukemic transformation process. A number of chromosomal translocations, particularly in lymphoid malignancies, result in ectopic or enhanced expression of genes located within the vicinity of the chromosomal breakpoints 10 .
This leads to over-expression of a protein, usually of normal sequence, although functionally significant mutations have been reported 11 .
In human precursor-B lymphoblastic acute leukemia (BCP-ALL), translocations involving the immunoglobulin heavy chain locus (IGH) at chromosomal band 14q32 is a rare but recurrent event. One such translocation, t(14;19)(q32;q13), has been previously described in six cases of BCP-ALL, in which the breakpoint on chromosome 19 differs from the t(14;19)(q32;q13)
identified in mature B-cell malignancies 12 . The "Groupe Francophone de Cytogénétique
Hématologique" (GFCH) has collected eight additional cases for hematological, cytogenetic 
Study design
Patient details are shown in Table 1 . Samples were obtained with informed consent. FISH analysis was performed as previously described 13 , using either BAC or commercially available IGH probes (LSI, IGH, Abbott Diagnostics, UK/France) 14 . Immunological, molecular and quantitative PCR analyses were performed as previously described 15, 16 . The fusion CEBPA-Cmu transcript was amplified using standard RT-PCR techniques with the primers CEBPA3 (AGGGGTGGAAACATAGGGACTT) and C1 (CCAACGGCCACGCTGCTC).
only.
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Results and discussion
Conventional chromosomal analysis identified eight patients with t(14;19)(q32;q13). Apart from one child, the patients were adults (median 38, range 22-76 years) with ALL, ranging from pro-B to pre-B immunophenotype. Myeloid markers tested were essentially negative (Supplementary table 1 Direct sequencing demonstrated the fusion of Cmu-JH to the 3' UTR of CEBPA, establishing unequivocally that CEBPA was the gene involved in the t(14;19) ( figure 1C) .
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To confirm the expression of CEBPA at the protein level, whole cell extracts were analyzed by Western blotting. The CEBPA protein was present as the two usual species, p42 and p30, of similar size to the U937 positive control ( Figure 1D and supplementary figure 3) . Thus, apparently normal CEBPA proteins are expressed in patients with t(14;19). This was expected as no mutation of the CEBPA gene was observed in patients (data not shown).
Our results indicate that CEBPA may act as an oncogene in lymphoid malignancies, in contrast to its role as a tumor suppressor in myeloid leukemia. A preliminary report has indicated that additional members of the CEBP family are involved in translocations with IGH in BCP-ALL, which may also exhibit oncogenic properties For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
